United Homes Group stock plunges after Nikki Haley, directors resign
Nuwellis, Inc. (NASDAQ:NUWE), a medical device company with a market capitalization of $3.6 million and current stock price of $3.97, announced Thursday that the United States Patent and Trademark Office issued U.S. Patent No. 12,415,021 on September 16. The patent covers the use of one or more hemolysis sensors with extracorporeal blood filtration systems, including ultrafiltration therapy and continuous renal replacement therapy (CRRT). The technology is designed to help detect and localize red blood cell destruction within or around the filtration circuit. According to InvestingPro data, the company maintains a strong liquidity position with more cash than debt on its balance sheet, though it’s currently experiencing rapid cash burn.
According to the company’s statement in the SEC filing, the intellectual property supports development of Nuwellis’s pediatric device, Vivian, as well as future platform innovation. The patent is based on Application No. 18/298,860.
Nuwellis is incorporated in Delaware and its common stock is traded on the Nasdaq Capital Market under the symbol NUWE. The company’s principal executive offices are located in Eden Prairie, Minnesota.
This information is based on a statement provided in a press release attached to the company’s Form 8-K filed with the Securities and Exchange Commission.
In other recent news, Nuwellis, Inc. has been granted a U.S. patent for technology that detects red blood cell destruction in blood filtration systems. This patent focuses on configurations using hemolysis sensors to determine the origin of hemolysis during treatments like ultrafiltration therapy. Additionally, Nuwellis received a $3 million grant from the National Institutes of Health to advance its pediatric kidney therapy device, Vivian, which targets patients with limited therapeutic options. The company also plans to launch a new 24-hour Aquadex therapy circuit this fall, designed for single-day outpatient sessions, complementing its existing 72-hour option. Furthermore, Nuwellis announced FDA clearance for a new size of its Dual Lumen Extended Length Catheter, though specific details on the size were not disclosed.
Meanwhile, New Era Energy & Digital, Inc. announced a significant development in its fiber network through a joint venture with Texas Critical Data Centers LLC. The venture signed a Memorandum of Understanding with GlobeLink Holdings to develop a 1,600-mile fiber optic network across Texas. This network aims to provide a substantial digital backbone for artificial intelligence, hyperscale, and cloud workloads in the region. These developments reflect ongoing advancements and strategic moves by both companies in their respective fields.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.